Arrowhead Pharmaceuticals, Inc. (ARWR) has a MoatMap StockRank of 72/100 based on Quality (74/100), Value (20/100), and Momentum (59/100) factor scores. The current signal is BUY. Arrowhead Pharmaceuticals is a clinical-stage biotechnology company. Its business model is characterized by high research and development costs, uncertain regulatory approvals, and dependence on a limited pipeline of products. It lacks a clear macro tailwind and does not fit the profile of a quality compounder.